VX-765: Selective Caspase-1 Inhibitor for Inflammation and Pyroptosis Research

Executive Summary: VX-765 is an orally absorbed pro-drug that is metabolized to VRT-043198, a potent and selective inhibitor of caspase-1 (ICE), enabling targeted suppression of IL-1β and IL-18 release while sparing other cytokines such as IL-6 and TNFα (Israelov et al. 2020). VX-765 shows robust efficacy in preclinical models of inflammatory and neurodegenerative diseases, including arthritis, skin inflammation, and blood-brain barrier (BBB) injury. It is a valuable tool for mechanistic studies of pyroptosis and caspase-1–dependent pathways in macrophages and lymphoid tissues. APExBIO supplies VX-765 (A8238), ensuring rigorous quality and detailed handling guidance (APExBIO product page). Quantitative assays confirm high solubility in DMSO and ethanol, with best storage at -20°C under desiccated conditions.

Biological Rationale

Caspase-1, also known as interleukin-1 converting enzyme (ICE), is a cysteine protease that processes pro-IL-1β and pro-IL-18 into their mature, secreted forms. This activity is central to the inflammasome pathway, a critical node in innate immunity and inflammation. Excessive or dysregulated caspase-1 activation contributes to the pathogenesis of autoimmune, infectious, and neurodegenerative diseases by triggering release of pro-inflammatory cytokines and by inducing pyroptosis, a lytic form of programmed cell death especially relevant in macrophages and infected lymphoid tissues (Israelov et al. 2020). Selective inhibition of caspase-1 enables experimental dissection of these pathways without broad suppression of immune responses, distinguishing VX-765 from pan-caspase or non-selective inhibitors. For a comprehensive review of the mechanistic context, see this article, which VX-765-focused research extends by integrating recent BBB and pyroptosis findings.

Mechanism of Action of VX-765

VX-765 is administered orally and absorbed as a pro-drug. In vivo, it is rapidly converted by esterases to its active metabolite, VRT-043198 (APExBIO). VRT-043198 binds selectively and reversibly to the catalytic site of caspase-1, inhibiting its proteolytic activity. This prevents cleavage of pro-IL-1β and pro-IL-18, thereby blocking their maturation and secretion. VX-765 demonstrates high selectivity for caspase-1 over related proteases, with minimal off-target effects on other caspases or cytokines such as IL-6, IL-8, TNFα, or IL-α. The compound does not inhibit caspase-8 or 9, as confirmed in endothelial cell viability rescue assays (Israelov et al. 2020, Table 1). The molecular specificity of VX-765 allows researchers to dissect ICE/caspase-1–mediated signaling and pyroptosis with high fidelity. For further molecular details, see the contrasted discussion in this article, which this review updates with blood-brain barrier–specific findings.

Evidence & Benchmarks

• VX-765 restored blood-brain barrier (BBB) integrity in vitro after paraoxon-induced injury by reducing PBMC adhesion, transmigration, and endothelial permeability (Israelov et al. 2020, DOI).
• In vivo, VX-765 administration in mice exposed to paraoxon normalized VE-cadherin expression and reduced pro-inflammatory cytokine release at the BBB (Israelov et al. 2020, DOI).
• In collagen-induced arthritis mouse models, VX-765 administration reduced IL-1β secretion, inflammatory infiltration, and histopathological scores (APExBIO, product page).
• VX-765 blocked CD4 T-cell pyroptosis in ex vivo HIV-infected human lymphoid tissues, reducing cell death in a dose-dependent manner (APExBIO, product page).
• Enzyme inhibition assays confirm an IC₅₀ in the low nanomolar range for human caspase-1 in buffered conditions at pH 7.5 (APExBIO, product page).

Compared to earlier reviews such as this article—which focused on competitive inhibitors—this article incorporates new translational benchmarks from BBB and HIV studies.

Applications, Limits & Misconceptions

VX-765 is used extensively in models of neuroinflammation, rheumatoid arthritis, and infectious diseases where caspase-1–mediated cytokine release and pyroptosis are implicated. Its oral bioavailability and selectivity make it suitable for both in vitro and in vivo experimental workflows. Recent studies highlight potential for therapeutic application in epilepsy and CNS disorders, pending further clinical validation (Israelov et al. 2020).

Common Pitfalls or Misconceptions

• VX-765 does not inhibit caspase-8 or caspase-9; its selectivity is confined to ICE/caspase-1 family enzymes (Table 1).
• It does not broadly suppress immune function; IL-6, IL-8, and TNFα remain largely unaffected (APExBIO).
• VX-765 is not water-soluble; it must be dissolved in DMSO (≥313 mg/mL) or ethanol (≥50.5 mg/mL, ultrasonic aid recommended).
• Long-term solution storage is discouraged; use freshly prepared solutions for optimal activity (handling guide).
• Effectiveness in human clinical disease remains under investigation; current evidence is preclinical.

Workflow Integration & Parameters

For bench workflows, VX-765 (A8238) is provided as a solid by APExBIO. It should be stored desiccated at -20°C. Solutions are best prepared in DMSO or ethanol immediately prior to use. Enzyme inhibition assays are typically conducted at pH 7.5 in buffered saline with stabilizing additives. In cell-based assays, titrate concentrations from nanomolar to micromolar range depending on cell type and endpoint. For in vivo studies, oral gavage is the preferred route, with established efficacy in murine models at doses ranging from 25 to 50 mg/kg/day (Israelov et al. 2020). For advanced integration strategies, see this workflow-focused review; this article updates assay recommendations for blood-brain barrier and pyroptosis models.

Conclusion & Outlook

VX-765 is a highly selective, orally available caspase-1 inhibitor that has transformed translational inflammation research. Its mechanistic specificity enables precise dissection of IL-1β and IL-18 pathways, as well as experimental modulation of pyroptosis and BBB integrity. Preclinical data support its utility in diverse disease models, though clinical translation is ongoing. APExBIO provides rigorously characterized VX-765 (A8238) for research use. Future work will further define its therapeutic potential and integration into disease-specific workflows.